/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

ACRIVON THERAPEUTICS, INC.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.29 0.0364(3.64%) ACRV at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 2.195
Highest Today 2.28
Today’s Open 2.25
Prev. Close 2.2
52 Week High 8.00
52 Week Low 1.05
Day’s Range: Low 2.195 High 2.28
52-Week Range: Low 1.05 High 8.00
1 day return -
1 Week return -3.79
1 month return +6.04
3 month return +74.04
6 month return +83.87
1 year return -66.37
3 year return -81.61
5 year return -
10 year return -

Institutional Holdings

RA Capital Management, LLC 26.52

Sands Capital Ventures, LLC 6.75

Citadel Advisors Llc 6.03

Wellington Management Company LLP 2.82

Vanguard Group Inc 1.89

Renaissance Technologies Corp 1.62

BlackRock Inc 1.30

Vanguard Total Stock Mkt Idx Inv 1.28

Jacobs Levy Equity Management, Inc. 1.22

Jane Street Group LLC 0.99

Millennium Management LLC 0.94

Marshall Wace Asset Management Ltd 0.58

Two Sigma Investments LLC 0.58

Geode Capital Management, LLC 0.52

Squarepoint Ops LLC 0.49

HRT FINANCIAL LLC 0.46

Goldman Sachs Group Inc 0.45

iShares Biotechnology ETF 0.40

Vanguard Institutional Extnd Mkt Idx Tr 0.39

XTX Topco Ltd 0.34

Fidelity Extended Market Index 0.23

State Street Corp 0.21

Charles Schwab Investment Management Inc 0.20

Schwab US Small-Cap ETF™ 0.20

Morgan Stanley - Brokerage Accounts 0.20

iShares Micro-Cap ETF 0.14

Extended Equity Market Fund K 0.13

Vifag 2002 SICAV 0.11

Fidelity Total Market Index 0.08

Fidelity Series Total Market Index 0.06

Fidelity Nasdaq Composite Index 0.06

Bridgeway Ultra-Small Company Market 0.06

Spartan Extended Market Index Pool F 0.05

iShares Nasdaq US Biotech ETF USD Acc 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

NT Col R2000 Val Idx Fd -DC -L -TierFour 0.04

NT Ext Equity Mkt Idx Fd - NL 0.04

Spartan Total Market Index Pool G 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.02

Market Status

Strong Buy: 4

Buy: 4

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 69.42 M

PB Ratio 0.5791

PE Ratio 0.0

Enterprise Value -51.79 M

Total Assets 196.59 M

Volume 310301

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY23:-50065000 -50.1M, FY22:-29677000 -29.7M, FY21:-16243000 -16.2M, FY20:-5306000 -5.3M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-300000 -0.3M, Q2/2025:-300000 -0.3M, Q1/2025:-311000 -0.3M, Q3/2024:null 0.0M, Q2/2024:-200000 -0.2M

Quarterly Net worth Q3/2025:-18234000 -18.2M, Q2/2025:-21006000 -21.0M, Q1/2025:-19680000 -19.7M, Q3/2024:-22441000 -22.4M, Q2/2024:-18798000 -18.8M

Fund house & investment objective

Company Information Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Organisation Biotechnology

Employees 75

Industry Biotechnology

CEO Dr. Peter Blume-Jensen M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow